Ista Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ista Pharmaceuticals, Inc. - overview
Established
1992
Location
Irvine, CA, US
Primary Industry
Pharmaceuticals
About
Ista Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for eye diseases, particularly in the area of ophthalmology, addressing unmet medical needs in eye health. Ista Pharmaceuticals, Inc. specializes in the development of pharmaceutical products for the treatment of eye diseases.
The company was founded in 1992 and is headquartered in Irvine, California, US. In March 2012, Bausch & Lomb, a portfolio company of Warburg Pincus and Welsh, Carson, Anderson & Stowe, acquired Ista Pharmaceuticals for approximately USD 500 mn. The acquisition deal was finalized in June 2012. The company has completed a total of 4 significant deals over its operational history, with the most recent deal occurring on March 26, 2012.
Ista Pharmaceuticals has raised a total of USD 65. 00 mn throughout its funding journey. Ista Pharmaceuticals, Inc. develops a range of medications specifically designed for the treatment of various eye conditions.
Their product portfolio includes treatments aimed at dry eye syndrome, glaucoma, and post-surgical recovery, focusing on enhancing patient comfort and improving vision outcomes. The company serves eye care professionals and patients globally, providing essential pharmaceutical solutions tailored to diverse ocular needs. In the most recent financial year, 2011, Ista Pharmaceuticals recorded a revenue of USD 160. 33 mn, with an EBITDA of USD 5.
76 mn. This financial performance underscores the company's capability to generate revenue through its specialized product offerings in the ophthalmic sector. Ista Pharmaceuticals, Inc. is poised for future growth through the continual development of new therapeutic products targeting various eye conditions.
The company is exploring new markets, particularly in Asia and Europe, aiming for expansion by 2014. The recent acquisition by Bausch & Lomb is expected to facilitate this growth strategy, leveraging additional resources and expertise to enhance product development and market penetration.
Current Investors
Warburg Pincus, Welsh, Carson, Anderson & Stowe, Bausch + Lomb Corporation
Primary Industry
Pharmaceuticals
Sub Industries
Drug Stores/Convenience Stores, Pharmaceutical Research & Development, Biomaterials
Website
www.istavision.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Ista Pharmaceuticals, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Ista Pharmaceuticals, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.